论文部分内容阅读
目的：探讨人卵巢癌标本中，肿瘤转移抑制基因ｎｍ２３－Ｈ１编码蛋白ＮＤＰＫ－Ａ表达的临床意义及其与预后的关系。方法：应用免疫组织化学抗生蛋白链菌素－过氧化酶结合（Ｓ－Ｐ）法，检测５８例人卵巢癌标本中ｎｍ２３－Ｈ１蛋白水平。结果：ｎｍ２３－Ｈ１蛋白的表达与患者手术时是否有淋巴结及大网膜转移相关（Ｐ＜０．０５），但原发灶与转移灶间的阳性表达率相差不显著；与患者术后生存时间密切相关（Ｐ＜０．０１），术后生存时间超过两年者，其阳性表达率明显高于不足两年者。结论：ｎｍ２３－Ｈ１基因产物在人卵巢癌的扩散和转移过程中确实发挥抑制作用，它在卵巢癌组织中的表达，可作为判断患者预后的有价值指标
Objective: To investigate the clinical significance of the expression of NDPK-A protein, a tumor metastasis suppressor gene nm23-H1, and its relationship with prognosis in human ovarian cancer specimens. Methods: Immunohistochemical streptavidin-peroxidase-binding (S-P) method was used to detect nm23-H1 protein levels in 58 human ovarian cancer specimens. RESULTS: The expression of nm23-H1 protein was associated with lymph node and greater omental metastasis during surgery (P<0.05), but the difference between the positive expression rate of primary tumor and metastasis was not significant. The time was closely related (P<0.01), and the postoperative survival time was more than two years. The positive expression rate was significantly higher than those with less than two years. Conclusion: The nm23-H1 gene product does inhibit the proliferation and metastasis of human ovarian cancer. The expression of nm23-H1 gene in ovarian cancer can be used as a valuable indicator to determine the prognosis of patients.